A total of 24 GC patients with HER2-positive receiving trastuzumab combination therapy were included in the study cohort, and their baseline clinicopathological characteristics were summarized and presented in Table 1 and Fig. 1 (median age 63 years, range 21–73; 79.2% of patients were male). This evidence concerns the gene ERBB2 and gastric cancer.